CAJ | 학술논문

目的：探讨吉西他滨、长春瑞滨联合吡喃阿霉素（GNT）方案对复发难治T细胞淋巴瘤（TCL）患者的疗效和毒副作用。方法：应用GNT方案治疗69例复发难治TCL患者，方案为吉西他滨800 mg/m2，d1、8，长春瑞滨25 mg/m2，d1，吡喃阿霉素20 mg/m2， d1，21天为1个周期。结果：总有效率（ORR）为65.2%，其中CR为29.0%。主要不良反应为血液学毒性。患者1、3、5年OS分别是71.7%、47.3%、32.4%，中位生存期为36个月。结论：GNT方案治疗复发难治TCL疗效较高、可耐受。
목적：탐토길서타빈、장춘서빈연합필남아매소（GNT）방안대복발난치T세포림파류（TCL）환자적료효화독부작용。방법：응용GNT방안치료69례복발난치TCL환자，방안위길서타빈800 mg/m2，d1、8，장춘서빈25 mg/m2，d1，필남아매소20 mg/m2， d1，21천위1개주기。결과：총유효솔（ORR）위65.2%，기중CR위29.0%。주요불량반응위혈액학독성。환자1、3、5년OS분별시71.7%、47.3%、32.4%，중위생존기위36개월。결론：GNT방안치료복발난치TCL료효교고、가내수。
Objective:This study was conducted to evaluate and discuss the curative effect and toxicity of gemcitabine, navel-bine, and therarubicin (GNT) regimen for patients with refractory or relapsed T-cell lymphoma (TCL). Methods:A total of 69 patients with refractory or relapsed TCL treated with GNT were enrolled. The treatment protocol was set as follows:800 mg/m2 gemcitabine ad-ministered at 1 and 8 d;25 mg/m2 navelbine administered at 1 d;and 20 mg/m2 therarubicin administered at 1 d. This protocol was re-peated every three weeks. The median cycle was 4 (range:2 to 6). Results:The overall response rate was 65.2%and the achieved com-plete remission was 29.0%. Hematology toxicities were the main adverse reactions observed in all of the patients. The incidence rates of grades 1 and 2 toxicity in leukopenia or neutropenia, anemia, and thrombocytopenia were 50.7%, 33.3%, and 26.1%, respectively. Grades 3 and 4 treatment-associated toxicities were detected in 23.1%of the responding patients. One-, three-, and five-year estimated overall survival (OS) of the whole cohort were 71.7%, 47.3%, and 32.4%, respectively. The median OS was 36 months. Conclusion:GNT was effective and suitable for patients with refractory or relapsed TCL.